OMNI 360 Wealth Inc. Makes New $364,000 Investment in Illumina, Inc. $ILMN

Key Points

• OMNI 360 Wealth Inc. made a new investment of $364,000 in Illumina, Inc. by acquiring 3,818 shares during the second quarter.
• Illumina reported $1.19 earnings per share (EPS) for the last quarter, exceeding estimates, but its revenue declined 4.8% year-over-year.
• Analysts have mixed ratings for Illumina's stock, with a consensus rating of "Hold" and a target price of $123.06.

OMNI 360 Wealth Inc. bought a new stake in Illumina, Inc. (NASDAQ:ILMN - Free Report) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor bought 3,818 shares of the life sciences company's stock, valued at approximately $364,000.

A number of other institutional investors and hedge funds also recently modified their holdings of the company. Centurion Wealth Management LLC raised its holdings in shares of Illumina by 42.5% in the 2nd quarter. Centurion Wealth Management LLC now owns 2,281 shares of the life sciences company's stock valued at $218,000 after purchasing an additional 680 shares during the period. Kera Capital Partners Inc. acquired a new position in Illumina in the 2nd quarter valued at about $387,000. Acadian Asset Management LLC grew its stake in Illumina by 171.2% in the 1st quarter. Acadian Asset Management LLC now owns 32,921 shares of the life sciences company's stock valued at $2,608,000 after buying an additional 20,784 shares during the last quarter. Bayforest Capital Ltd grew its stake in Illumina by 664.5% in the 1st quarter. Bayforest Capital Ltd now owns 3,058 shares of the life sciences company's stock valued at $243,000 after buying an additional 2,658 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Illumina by 51.7% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,960,385 shares of the life sciences company's stock valued at $155,537,000 after buying an additional 667,978 shares during the last quarter. 89.42% of the stock is owned by institutional investors.

Illumina Stock Performance

NASDAQ ILMN opened at $95.12 on Friday. The company has a current ratio of 1.81, a quick ratio of 1.41 and a debt-to-equity ratio of 0.66. The firm has a market capitalization of $14.62 billion, a price-to-earnings ratio of 12.04, a P/E/G ratio of 2.23 and a beta of 1.43. The firm's 50 day simple moving average is $99.46 and its 200 day simple moving average is $88.53. Illumina, Inc. has a 1 year low of $68.70 and a 1 year high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The life sciences company reported $1.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.17. The business had revenue of $1.06 billion for the quarter, compared to analyst estimates of $1.12 billion. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The firm's revenue for the quarter was down 4.8% on a year-over-year basis. During the same quarter last year, the business posted $0.36 EPS. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. As a group, research analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the stock. Daiwa Capital Markets lowered shares of Illumina from an "outperform" rating to a "neutral" rating and set a $94.00 price target on the stock. in a research note on Tuesday, August 12th. Citigroup lowered shares of Illumina from a "hold" rating to a "strong sell" rating and decreased their price target for the company from $85.00 to $80.00 in a research note on Wednesday, July 9th. Stephens set a $110.00 target price on shares of Illumina and gave the stock an "overweight" rating in a research report on Monday, August 4th. Royal Bank Of Canada set a $124.00 target price on shares of Illumina in a research report on Tuesday, September 2nd. Finally, Scotiabank lowered shares of Illumina from a "sector outperform" rating to a "sector perform" rating and set a $125.00 target price on the stock. in a research report on Friday, July 11th. Six investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Illumina has a consensus rating of "Hold" and a consensus target price of $123.06.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.